|
TNFRSF11B
|
0.500 |
Biomarker
|
disease |
BEFREE |
The probable positive effects of photobiomodulation therapy (PBMT) and oxytocin (OT) treatments together or alone were evaluated on cell viability along with the changes in the gene expression of Osteocalcin (OC), Osteoprotegerin (OPG), and Runt-related transcription factor 2 (Runx2) levels of sham (healthy)-Bone marrow mesenchymal stem cell(BMMSC) and ovariectomy-induced osteoporosis (OVX)-BMMSC.
|
31399862 |
2020 |
|
TNFRSF11B
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
H. pluvialis fractions rich in astaxanthin ameliorated bone loss in experimentally-induced osteoporosis in rats probably through the down-regulation of serum OPG in concurrence with up-regulation of serum RANKL.
|
31158803 |
2019 |
|
TNFRSF11B
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
All of the above indicate that oral administration of icariin can prevent diabetic osteoporosis; the effect is mainly related to its ability to reduce blood glucose, inhibit bone turnover and bone marrow adipogenesis, as well as up-regulate bone RUNX 2, and OPG expression.
|
31096652 |
2019 |
|
TNFRSF11B
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our results suggest that autologous USC-EVs represent a promising novel therapeutic agent for osteoporosis by promoting osteogenesis and inhibiting osteoclastogenesis by transferring CTHRC1 and OPG.
|
31263627 |
2019 |
|
TNFRSF11B
|
0.500 |
Biomarker
|
disease |
BEFREE |
<b>Objectives:</b> We explored the interactions of osteoprotegerin (OPG) with biomarkers of bone turnover and cytokines, including soluble receptor activator for nuclear factor kappa beta ligand (sRANKL), tumor necrosis factor-related apoptosis-induced ligand (TRAIL), and Wnt inhibitors in osteoporosis, vasculopathy and fibrosis related to systemic sclerosis (SSc).
|
30001654 |
2019 |
|
TNFRSF11B
|
0.500 |
Biomarker
|
disease |
BEFREE |
RANKL was higher and OPG/RANKL was lower in TM patients compared to osteoporosis group.
|
30868952 |
2019 |
|
TNFRSF11B
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The risk of osteoporosis was also higher in the G-allele carrier of the OPG-rs3102735 polymorphism than in individuals with the AA genotype (AG/GG vs. AA) (adjusted OR [95% CI] = 1.65 [1.27-2.14]).
|
30624097 |
2019 |
|
TNFRSF11B
|
0.500 |
Biomarker
|
disease |
BEFREE |
Moreover, treatment with cimiracemate A attenuates the expression of receptor activator of nuclear factor kappa-Β ligand (RANKL), receptor activator of nuclear factor κ B (RANK), and osteoprotegerin (OPG) protein in glucocorticoid-induced osteoporosis rats.
|
30695776 |
2019 |
|
TNFRSF11B
|
0.500 |
Biomarker
|
disease |
BEFREE |
The osteoprotegerin (OPG) gene has been reported to be associated with the BMD and pathogenesis of osteoporosis.
|
30572450 |
2018 |
|
TNFRSF11B
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Treatments of ovariectomy-induced osteoporosis mice with gossypol significantly increased serum osteocalcin and osteoprotegerin (OPG) levels; meanwhile they decreased serum RANKL levels.
|
30643801 |
2018 |
|
TNFRSF11B
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We suggest for the first time a protective role against osteoporosis in GD1 patients for the CC genotype of the c.9C>G gene variant in the TNFRSFB11 (OPG) gene and for the CC genotype of the c.1340T>C gene variant (CALCR gene), while the AA genotype of the c.1024+283G>A gene variant in the VDR gene appears as a risk factor for lower BMDs.
|
30498352 |
2018 |
|
TNFRSF11B
|
0.500 |
Biomarker
|
disease |
BEFREE |
To examine the effect of SNPs clustered within key pathways associated with the development of osteoporosis, subtype weighted GRS specific to WNT signaling (6 SNPs), RANK-RANKL-OPG (3 SNPs), and mesenchymal stem differentiation (3 SNPs) were generated for analysis.
|
29713799 |
2018 |
|
TNFRSF11B
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The protein-protein interactions between receptor activator of nuclear factor-κB ligand (RANKL), RANK (its receptor), and osteoprotegerin (OPG), are known to mediate the development and activation of osteoclasts in bone remodeling, and are regarded as a pivotal therapeutic target for the treatment of osteoporosis.
|
29348072 |
2018 |
|
TNFRSF11B
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
This paper contrasted their anti-osteoporosis activity from the perspective of their affinity to OPG/RANKL protein targets.
|
30036771 |
2018 |
|
TNFRSF11B
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Single-nucleotide polymorphism (SNP) rs2073618 in the <i>TNFRSF11B</i> osteoprotegerin (<i>OPG</i>) gene has been related to postmenopausal OP although, to date, no information has been described concerning whether this polymorphism is implied in abnormalities of bone mineral density (BMD) in RA.
|
28758134 |
2017 |
|
TNFRSF11B
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recently, ISI disruption has been linked to osteoporosis in human immunodeficiency virus (HIV) infection/acquired immunodeficiency syndrome (AIDS), where elevated B cell RANKL and diminished OPG drive bone resorption.
|
29046115 |
2017 |
|
TNFRSF11B
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The study group comprised patients with osteoporosis, in order to evaluate the association between OPG serum levels and cardiovascular pathology.
|
28849089 |
2017 |
|
TNFRSF11B
|
0.500 |
Biomarker
|
disease |
BEFREE |
The development of autoantibodies to OPG (OPG-Ab) has been associated with severe osteoporosis and increased bone resorption in rheumatoid arthritis.
|
28534161 |
2017 |
|
TNFRSF11B
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Relationship between A163G osteoprotegerin gene polymorphism and other osteoporosis parameters in Roma and non-Roma postmenopausal women in eastern Slovakia.
|
27859736 |
2017 |
|
TNFRSF11B
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In the study, we first assessed the relationship between OPG variants and BMD or osteoporosis fractures in our sample size (227 subjects with postmenopausal osteoporosis and 189 controls), and then performed a systematic meta-analysis.
|
28496203 |
2017 |
|
TNFRSF11B
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Overall, no significant associations could be detected between OPG T950C polymorphism and osteoporosis when all included studies were pooled into this meta-analysis.
|
29253005 |
2017 |
|
TNFRSF11B
|
0.500 |
Biomarker
|
disease |
BEFREE |
The study objective was to assess the OPG role related to uremic osteoporosis in HD patients.
|
28161839 |
2017 |
|
TNFRSF11B
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The effect of BP on clinical findings and gingival crevicular fluid (GCF) values of RANKL and OPG using enzyme-linked immunosorbent assays was evaluated in postmenopausal women; 13 patients with both chronic periodontitis and osteoporosis (group A), 12 systemically healthy patients with chronic periodontitis (group B), 12 periodontally healthy patients with osteoporosis (group C), and 10 systemically and periodontally healthy individuals (group D).
|
28367895 |
2017 |
|
TNFRSF11B
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The BMD, SOD and GSH⁃Px levels, and the expression of OPG were significantly lower in osteoporosis compared to control group (all p < 0.05).
|
29055350 |
2017 |
|
TNFRSF11B
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Effect of OPG gene mutation on protein expression and biological activity in osteoporosis.
|
28810612 |
2017 |